{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-233432","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2023-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.592875+00:00","generated_at":"2026-06-10T20:34:25.342531+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"low","headline":"Lyra posts slide deck with BEACON Phase 2 topline results for LYR-220 in CRS","bullets":["LYR-220 evaluated in Phase 2 BEACON study for chronic rhinosinusitis with/without polyps in patients with prior ethmoidectomy.","Topline results posted as slide deck on Lyra investor website on Sept 12, 2023; no specific data included in this 8-K text.","Study identifier NCT05035654 on clinicaltrials.gov; two-part, patient-blinded, randomized trial.","No financial impact or guidance changes announced; materiality depends on the actual results not seen here."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-233432","json":"https://secwatch.observer/filing/0001193125-23-233432.json","markdown":"https://secwatch.observer/filing/0001193125-23-233432.md","text":"https://secwatch.observer/filing/0001193125-23-233432.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000119312523233432/0001193125-23-233432-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000119312523233432/d536466d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T20:34:25.342531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}